1 completed. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
Follow Genz-644282: new trials by email Literature Review of Genz-644282 trials Research Report on Genz-644282
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors Genz-644282 (28-day dosing schedule), Genz-644282 (21-day dosing schedule) - Solid Tumors | Phase 1 | Completed | Genzyme, a Sanofi Company | 87 | 2009-07-01 | 2014-03-19 |
Metatropic dwarfism (1) · Neoplasms (1)
United States (1)